TransMedics Group Future Growth
Future criteria checks 5/6
TransMedics Group is forecast to grow earnings and revenue by 31.7% and 18.5% per annum respectively. EPS is expected to grow by 29.2% per annum. Return on equity is forecast to be 20.2% in 3 years.
Key information
31.7%
Earnings growth rate
29.2%
EPS growth rate
| Medical Equipment earnings growth | 16.8% |
| Revenue growth rate | 18.5% |
| Future return on equity | 20.2% |
| Analyst coverage | Good |
| Last updated | 17 Dec 2024 |
Recent future growth updates
Recent updates
With A 30% Price Drop For TransMedics Group, Inc. (NASDAQ:TMDX) You'll Still Get What You Pay For
Dec 28
TransMedics Faces Market Turbulence As Growth Engines Stutter
Dec 04These 4 Measures Indicate That TransMedics Group (NASDAQ:TMDX) Is Using Debt Reasonably Well
Nov 20TransMedics: Long-Term Thesis Hasn't Changed At All
Nov 19TransMedics: Overreaction To Temporary Headwinds (Rating Upgrade)
Nov 12What You Can Learn From TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S After Its 44% Share Price Crash
Oct 30TransMedics: Mistakes Have Been Made, Here's My Updated Outlook
Oct 29TransMedics' Organ Care: Critical Innovation With Lofty Expectations
Oct 23TransMedics Group: This Could Be One Of The Biggest Moats In A Decade
Oct 16Returns Are Gaining Momentum At TransMedics Group (NASDAQ:TMDX)
Sep 18TransMedics: Take Profits While The Valuation Is Sky High
Sep 18TransMedics: Wide Moat Player At A Lower Valuation Than Peers
Sep 10TransMedics Group, Inc.'s (NASDAQ:TMDX) P/S Is Still On The Mark Following 25% Share Price Bounce
Aug 28TransMedics: Heart And Lungs Will Drive The Next Leg Higher
Aug 19Analysts Just Made A Meaningful Upgrade To Their TransMedics Group, Inc. (NASDAQ:TMDX) Forecasts
Aug 06TransMedics Group: Providing Long-Term Detailed Forecast And Upgrading To Buy
Aug 04TransMedics Group, Inc. Just Recorded A 66% EPS Beat: Here's What Analysts Are Forecasting Next
Aug 02TransMedics Group Stock: Too Far, Too Fast
Jul 08TransMedics: NOP, Logistics And Transport Are Key Growth Drivers But Stock Is Pricey
Jun 17TransMedics Group (NASDAQ:TMDX) Might Have The Makings Of A Multi-Bagger
Jun 10TransMedics: Transportation Supporting Growth
May 21TransMedics Group: Looking At The Road Ahead After An Exceptional Q1 (Rating Downgrade)
May 06TransMedics Group, Inc. (NASDAQ:TMDX) Stocks Shoot Up 27% But Its P/S Still Looks Reasonable
Apr 24TransMedics Group: Founder Led Company With Solid Potential
Apr 19Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 11TransMedics Group: Emerging Medical Device Market Leader With A Long Growth Runway
Mar 19TransMedics Group: Huge Opportunity In Organ Transplants
Mar 12TransMedics: A Very Expensive Growth Stock
Feb 07With TransMedics Group, Inc. (NASDAQ:TMDX) It Looks Like You'll Get What You Pay For
Jan 23Calculating The Fair Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Jan 02Does TransMedics Group (NASDAQ:TMDX) Have A Healthy Balance Sheet?
Nov 05This Just In: Analysts Are Boosting Their TransMedics Group, Inc. (NASDAQ:TMDX) Outlook for This Year
Aug 06TransMedics Group (NASDAQ:TMDX) Has Debt But No Earnings; Should You Worry?
Aug 02TransMedics Group, Inc. (NASDAQ:TMDX) Not Lagging Industry On Growth Or Pricing
Jun 29Brokers Are Upgrading Their Views On TransMedics Group, Inc. (NASDAQ:TMDX) With These New Forecasts
May 06Is TransMedics Group (NASDAQ:TMDX) Using Too Much Debt?
Apr 27Estimating The Intrinsic Value Of TransMedics Group, Inc. (NASDAQ:TMDX)
Apr 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 633 | 85 | 98 | 121 | 8 |
| 12/31/2025 | 522 | 48 | 20 | 71 | 9 |
| 12/31/2024 | 429 | 34 | -58 | 62 | 9 |
| 9/30/2024 | 401 | 33 | -121 | 37 | N/A |
| 6/30/2024 | 359 | 3 | -221 | 24 | N/A |
| 3/31/2024 | 297 | -10 | -230 | -8 | N/A |
| 12/31/2023 | 242 | -25 | -192 | -13 | N/A |
| 9/30/2023 | 192 | -36 | -165 | -25 | N/A |
| 6/30/2023 | 151 | -18 | -41 | -33 | N/A |
| 3/31/2023 | 119 | -28 | -47 | -36 | N/A |
| 12/31/2022 | 93 | -36 | -58 | -46 | N/A |
| 9/30/2022 | 72 | -42 | -61 | -48 | N/A |
| 6/30/2022 | 51 | -48 | -53 | -43 | N/A |
| 3/31/2022 | 39 | -47 | -45 | -40 | N/A |
| 12/31/2021 | 30 | -44 | -32 | -29 | N/A |
| 9/30/2021 | 28 | -38 | -30 | -29 | N/A |
| 6/30/2021 | 30 | -30 | -27 | -26 | N/A |
| 3/31/2021 | 25 | -28 | -30 | -29 | N/A |
| 12/31/2020 | 26 | -29 | -31 | -30 | N/A |
| 9/30/2020 | 24 | -32 | -31 | -30 | N/A |
| 6/30/2020 | 24 | -35 | -30 | -30 | N/A |
| 3/31/2020 | 26 | -36 | -34 | -33 | N/A |
| 12/28/2019 | 24 | -34 | -32 | -32 | N/A |
| 9/28/2019 | 21 | -32 | -31 | -31 | N/A |
| 6/29/2019 | 18 | -29 | -32 | -32 | N/A |
| 3/30/2019 | 15 | -26 | -27 | -27 | N/A |
| 12/29/2018 | 13 | -24 | -26 | -26 | N/A |
| 9/29/2018 | 12 | -21 | N/A | -25 | N/A |
| 6/30/2018 | 9 | -20 | N/A | -24 | N/A |
| 3/31/2018 | 8 | -20 | N/A | -23 | N/A |
| 12/30/2017 | 8 | -21 | N/A | -23 | N/A |
| 12/31/2016 | 6 | -24 | N/A | -24 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TMDX's forecast earnings growth (31.7% per year) is above the savings rate (2.6%).
Earnings vs Market: TMDX's earnings (31.7% per year) are forecast to grow faster than the US market (15.3% per year).
High Growth Earnings: TMDX's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: TMDX's revenue (18.5% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: TMDX's revenue (18.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TMDX's Return on Equity is forecast to be high in 3 years time (20.2%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:19 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
TransMedics Group, Inc. is covered by 13 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Rescott | Baird |
| William Plovanic | Canaccord Genuity |
| Kristen Stewart | CL King & Associates, Inc. |